elaboration. Aspirin can also directly scavenge hydroxyl radicals to form the 2, 3-and 2, 5-
dihydroxybenzoate derivatives, which themselves serve as markers of oxidative stress25 …

Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A 2
and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance …

Aspirin and the thienopyridines ticlopidine and clopidogrel are antiplatelet agents that
display good antithrombotic activity. In the past few years, the concept of aspirin resistance …

Antiplatelet therapy is a cornerstone of cardiovascular medicine. Aspirin and clopidogrel
have emerged as critical therapies in the treatment of cardiovascular disease. Despite their …

BACKGROUND: The absolute risk of recurrences among patients using aspirin for
prevention of cardiovascular events remains high. Persistent platelet reactivity despite …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• A genetic basis for aspirin resistance
has been postulated to exist.• The individual studies published have been too small to allow …

BACKGROUND AND PURPOSE: The prevalence of antiplatelet drug resistance among
patients who undergo cerebrovascular stent placement is unknown. We aimed to assess the …

INTRODUCTION: There is wide variability in the responses of individual patients to aspirin
and clopidogrel. Polymorphisms of several platelet receptors have been related to increased …

Aspirin-induced cyclooxygenase (COX)-1 acetylation is irreversible and it is assumed that
the platelet thromboxane-A2 aggregation pathway is inhibited for at least 24 hours (h) after …

Background and Purpose—The widespread use of aspirin requires clarification of the
aspirin resistance phenomenon. Most studies on this field are focused on patients which …